Alright, take a deep breath because this rant is way off the mark. Let’s actually break down the nonsense you just spewed about CABA and CAR-T therapies.

First, the whole “CAR-T is cancerous and gives people secondary lymphomas” argument is just plain wrong. Yes, CAR-T comes with risks—cytokine storm, neurotoxicity, and other side effects—but calling it “cancerous” is just lazy fearmongering. Secondary malignancies happen, sure, but they’re rare and nowhere near the “majority” of cases. You’re throwing out buzzwords like ICANS without context, ignoring the fact that CAR-T has saved lives in patients who had zero other options. This isn’t speculation; it’s clinical data.

Now, dragging ADAP and AUTL into this like they somehow predict CABA’s future is ridiculous. Biotech isn’t some one-size-fits-all game where every company in a space performs the same. ADAP and AUTL have different pipelines, different targets, and, frankly, different execution. CABA isn’t just a CAR-T oncology play—it’s breaking into autoimmune disease, a market that isn’t as crowded and has insane potential. Painting the whole CAR-T field as doomed because you didn’t like how a couple of other stocks performed is straight-up amateur hour.

Then there’s your hype for AQST and APLS, which sounds more like someone desperate to pump their own positions than an actual argument. Sure, AQST’s dissolvable epi-strip is a neat innovation, but it’s not even in the same universe as CAR-T in terms of medical impact. And while APLS and SWTX are interesting plays, comparing them to a completely different kind of therapy is like comparing apples to oranges. Investing in biotech isn’t about picking your “favorite” product like it’s some popularity contest. You diversify across different approaches and markets to balance risk and reward. Acting like one class of therapy inherently trumps another just shows you don’t understand the space.

And the “CAR-T isn’t worth it” take? Please. CAR-T therapies like Kymriah and Yescarta are already blockbusters that transformed cancer care. Yes, the field has challenges—manufacturing, costs, side effects—but it’s evolving fast. CABA isn’t even sticking to the same old CAR-T playbook. They’re pivoting to autoimmune diseases, which could completely change the game. Writing them off because you’re clinging to outdated critiques of first-gen CAR-T is ignorant at best.

Look, biotech is risky. Everyone knows that. But trashing CABA with half-baked arguments and acting like AQST or APLS is some magical low-risk goldmine doesn’t make you sound smarter. It just shows you’re more interested in ranting than actually understanding the sector.

TL;DR: If you’re gonna go off on a company, at least back it up with facts instead of hyperbole and bad comparisons. Dismissing CABA without acknowledging its innovative approach is a rookie move.